Initial Evaluation of New Antiarrhythmic Agents in Man: Normal Volunteers or Patients?

[1]  R. Goldstein,et al.  Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. , 1983, The American journal of cardiology.

[2]  R. Winkle,et al.  Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia. , 1983, Circulation.

[3]  L. Horowitz,et al.  Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. , 1982, The American journal of cardiology.

[4]  E. Prystowsky,et al.  Electrophysiology of oral encainide. , 1982, The American journal of cardiology.

[5]  R. Winkle.  CLINICAL EFFICACY OF ANTIARRHYTHMIC DRUGS IN PREVENTION OF SUDDEN CORONARY DEATH , 1982, Annals of the New York Academy of Sciences.

[6]  R. Winkle,et al.  Malignant ventricular tachyarrhythmias associated with the use of encainide. , 1981, American heart journal.

[7]  L. Weissman.  Multiple‐Dose Phase I Trials—Normal Volunteers or Patients? One Viewpoint , 1981, Journal of clinical pharmacology.

[8]  C. George.  The importance of clinical pharmacology in drug development. , 1981, Clinical science.

[9]  R. Campbell,et al.  ORAL MEXILETINE IN HIGH-RISK PATIENTS AFTER MYOCARDIAL INFARCTION , 1980, The Lancet.

[10]  B. Pitt,et al.  Kinetics of antifibrillatory effects of bretylium: correlation with myocardial drug concentrations. , 1980, The American journal of cardiology.

[11]  D. Roden,et al.  Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. , 1980, The American journal of cardiology.

[12]  D. Roden,et al.  Tocainide therapy for refractory ventricular arrhythmias. , 1980, American heart journal.

[13]  N. Carliner,et al.  Lidocaine and its active metabolites , 1978, Clinical pharmacology and therapeutics.

[14]  R. Vestal,et al.  Direct measurement of propranolol bioavailability during accumulation to steady-state. , 1978, British journal of clinical pharmacology.

[15]  D. Drayer,et al.  Steady‐state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function , 1978, Clinical pharmacology and therapeutics.

[16]  R. Gugler,et al.  Phenytoin: Pharmacokinetics and bioavailability , 1976, Clinical pharmacology and therapeutics.

[17]  R. Arcidiacono,et al.  Chemical ventricular defibrillation of the human heart with bretylium tosylate. , 1973, The American journal of cardiology.

[18]  J. Oates.  A scientific rationale for choosing patients rather than normal subiects for Phase I studies , 1972, Clinical pharmacology and therapeutics.

[19]  D. Azarnoff.  Physiologic factors in selecting human volunteers for drug studies , 1972, Clinical pharmacology and therapeutics.